Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Digestive & weight
What benefits of BPC-157 are under study?
BPC-157 benefits under study include tendon, gut, muscle, joint, skin, and nerve recovery. See what lab, animal, and early human research has found.
Quick answer
Researchers are studying BPC-157 for tendon and ligament, gut, muscle, joint, wound, and nerve healing. Most findings come from laboratory and animal research. There, BPC-157 has been linked with faster, more complete healing across many injury models. Human research is getting started, with three small pilot studies published. A controlled rotator cuff repair trial is registered. BPC-157 is not an FDA-approved drug and has no established labeled route. The World Anti-Doping Agency prohibits it in sport.
- Published
- November 4, 2026
- Last updated
- November 4, 2026
Benefits and uses researchers are exploring
Researchers are studying possible BPC-157 benefits for tendons and ligaments, gut health, muscle injuries, joint pain, wound healing, and nerve injuries. Most published findings come from laboratory and animal research, and the first human pilot studies1 have now been published.
Body Protection Compound-157 is a 15-amino-acid peptide originally isolated from gastric juice1. It is best known for recovery. Interest centers on tendons and ligaments, which have sparse blood supply2 and heal slowly.
People who use BPC-157 often describe less pain, easier movement, and a quicker return to training. Those experiences drive much of its popularity, and tracking pain and strength puts each recovery in context.
BPC-157 and tendon and ligament healing
BPC-157 has been linked with stronger, better-organized healing of cut tendons3 and ligaments in rats.
Rats with a cut Achilles tendon received daily intraperitoneal (abdominal) BPC-157 injections. Over 14 days, rats given BPC-157 outperformed saline controls on strength, walking, collagen, and defect size.
Rats with a cut knee ligament got BPC-157 by intraperitoneal injection, in drinking water, or as a cream. Each route was linked with better ligament healing over 90 days4.
In cultured rat tendon cells, BPC-157 raised survival under stress and cell migration5, two processes linked to tendon healing.
BPC-157's gut studies used a similar mix of routes.
BPC-157 and gut health
In rat models of bowel injury, BPC-157 has been linked with healing that control rats did not show6.
- Colitis and bowel surgery: Rats with chemical colitis or a surgically joined colon showed healing on intraperitoneal or oral BPC-157.
- Fistula: Rats with a surgical colon-to-skin tract showed fistula closure7 on oral or intraperitoneal BPC-157 for up to 28 days.
- Reduced blood flow: BPC-157 applied onto rat colon with tied-off blood supply was linked with faster vessel reconnection8.
Rat studies also cover injured skeletal muscle.
BPC-157 and muscle injury recovery
In rats with a crushed calf muscle9, BPC-157 was linked with faster healing and better leg function than in control rats.
Rats received daily intraperitoneal or topical BPC-157 for up to 14 days. Rats given BPC-157 had less bruising and swelling, no leg contracture, and better healing under the microscope.
Joint research, unlike these acute-injury studies, centers on inflammation.
What studies show about BPC-157 and joint pain
BPC-157 has reduced arthritis lesions in rats10, and an early clinic report describes knee pain improvement in people.
Rats with adjuvant arthritis, an inflammatory model, got single or daily intraperitoneal doses. In established disease, effects began by two weeks and were still seen after a year of dosing.
One clinic reviewed the charts of 17 patients11 given BPC-157 knee injections, reaching 16 by phone, mostly six months to one year later. Most patients given BPC-157 alone reported less knee pain, an early result controlled trials can build on.
Burns, by contrast, give researchers a visible wound to measure.
BPC-157 and wound healing in burn studies
BPC-157 applied to the skin was linked with faster, more complete burn healing in mice12 and rats.
Mice with deep burns over about 20% of the body received BPC-157 cream. At two weeks, they had less swelling and dead tissue, more vessels and collagen, and better skin regrowth than control mice.
Rats with alkali (chemical) skin burns given topical BPC-157 showed faster wound closure and more collagen13 by day 18.
Rodent research on BPC-157 also extends to brain and nerve injuries.
BPC-157 and the brain and nervous system
BPC-157 has been linked with less damage and better recovery of movement14 after rodent nerve injuries.
- Brain injury: Mice dosed intraperitoneally before a falling-weight injury had less brain bleeding and swelling15 over 24 hours.
- Peripheral nerve: Rats with a cut sciatic nerve walked better over one to two months on injected, oral, or local BPC-157.
- Spinal cord: Rats given one intraperitoneal dose after tail-level spinal cord compression regained tail movement16, with follow-up to 360 days.
Researchers are now taking these findings into human studies.
What has human research found on BPC-157 benefits?
Human research on BPC-157 began with three small published pilot studies1, in knee pain, bladder pain, and intravenous safety. In the bladder pain (interstitial cystitis) pilot17, 10 of 12 women reported their symptoms resolved. Each had one procedure injecting BPC-157 around inflamed areas of the bladder.
| Research area | Laboratory and animal findings | Human research |
| Tendon and ligament | Better healing of cut Achilles tendon and knee ligament in rats | Rotator cuff surgery pilot trial18 registered, not yet recruiting |
| Gut | Healing of colitis, fistulas, and surgical bowel joins in rats | 2-week ulcerative colitis enema trial, 53 randomized, published as a meeting abstract; FDA's 2026 review19 found too little clinical data to draw a conclusion |
| Muscle | Faster crush-injury healing and better leg function in rats | No published human studies yet |
| Joint pain | Fewer adjuvant arthritis lesions in rats | Knee injection chart review of 17 patients11 |
| Wound | Faster burn healing in mice and rats | No published human studies yet |
| Brain and nervous system | Brain, nerve, and spinal cord injury recovery in rodents | No published human studies yet |
| Safety | No adverse effects reported in preclinical safety studies20 | 2-adult, 3-day intravenous pilot21 reported no side effects or lab changes, a starting point for human safety data |
The rotator cuff repair trial is designed to test whether animal results carry over to people.
The World Anti-Doping Agency (WADA) prohibits BPC-157 at all times22 as a non-approved substance. Athletes subject to drug testing can face sanctions for using it. Check current WADA and league rules before considering BPC-157.
Getting BPC-157 in 2026
Superpower will offer BPC-157 formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. A licensed clinician will assess whether it fits each person's health care. Anyone interested can join the Superpower peptide waitlist now.
BPC-157 is not an FDA-approved drug. In October 2026, the Department of Health and Human Services announced it does not intend to take enforcement action23 against state-licensed pharmacies compounding BPC-157 while the 503A Bulks List, which sets the ingredients pharmacies may use in compounding, is finalized. BPC-157 is one of six peptides the policy covers24, under conditions that include ingredients from FDA-registered facilities and a patient-specific prescription. The policy came after a July 2026 FDA advisory committee recommended adding BPC-157 to the list25, and rulemaking is still underway.